Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TOP1 | P11387 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12942621 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL11001929 | 0.82 | LMNA (0.50) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL14228222 | 0.81 | TOP1 (0.46) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL5260439 | 0.80 | — | — | |
| SCHEMBL16264448 | 0.80 | LMNA (0.48) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL24715153 | 0.79 | LMNA (0.52) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL25934859 | 0.79 | LMNA (0.52) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL12790404 | 0.79 | LMNA (0.52) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL4754912 | 0.78 | LMNA (0.58) | LMNAL3MBTL1TDP1TOP1KDM4E | |
| SCHEMBL22961915 | 0.78 | LMNA (0.58) | LMNAL3MBTL1TDP1TOP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-7265086-B2 | Glycopeptide carboxy-saccharide derivatives | THERAVANCE, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265086-B2 | Glycopeptide carboxy-saccharide derivatives | THERAVANCE, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070042942-A1 | Glycopeptide carboxy-saccharide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-02-22 | — | — | US | disclosed |
| US-20070042942-A1 | Glycopeptide carboxy-saccharide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042942-A1 | Glycopeptide carboxy-saccharide derivatives | CSGALNACT1, FUT6, OGT | LMNA 4124/4885L3MBTL1 1837/4885TDP1 2438/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | LMNA 4466/4885L3MBTL1 3585/4885TDP1 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.